Skip to content

Study · Ex vivo tissue · 1985

2 results

In vitro immune modulation by thymosin alpha 1 in patients with head and neck squamous cell carcinoma.

Wolf GT, Peterson KA, Lovett EJ 3rd

Head & neck surgery1 May 1985Cited by 3 (Europe PMC)

PMID3879957 (opens in a new tab)DOI10.1002/hed.2890070503 (opens in a new tab)PepBankPUB-03879957
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabEx vivo tissueEfficacy outcome

    In vitro, thymosin alpha‑1 was associated with improved leukocyte migration inhibition in patients with head and neck squamous cell carcinoma.

    In plain wordsIn lab tests on blood cells taken from head and neck cancer cases, thymosin alpha‑1 was linked to better immune cell migration response.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseLeukocyte migration inhibition in response to PHA
    Study

    humann: not reported in source

    leukocytes from patients with head and neck squamous cell carcinoma
    Outcome group
    Immune response · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Thymosin alpha 1, in vitro, was associated with improvement in LMI in the cancer patients.
  2. 02LabEx vivo tissueMechanism

    In vitro improvements in migration response with thymosin alpha‑1 appeared independent of the levels of T-lymphocyte subpopulations.

    In plain wordsIn lab tests, the improvement from thymosin alpha‑1 did not seem to depend on T-cell subset levels.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeDependence of migration response improvement on T-lymphocyte subset levels
    Study

    humann: not reported in source

    leukocytes from patients with head and neck squamous cell carcinoma
    Outcome group
    Immune response · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Improvements in migration response with thymosin alpha 1 appeared to be independent of levels of various T-lymphocyte subpopulations.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.